Patel Anish
SEC CIK 1967163 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | COO | 20.0K | — | $5.90M | 36 | 2023-02-23 | 2026-02-12 |
Most active insiders at ELVN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10% | — | $51.68M |
| 2 | Derynck Mika K | Dir | — | $9.56M |
| 3 | Collins Helen Louise | Chief MEDICAL Off | — | $5.39M |
| 4 | Lyssikatos Joseph P | CSO | — | $4.88M |
| 5 | Patel Anish | COO | — | $1.74M |
| 6 | Hohl Benjamin | CFO | — | $1.60M |
| 7 | Kunkel Lori Anne | Dir | — | $850.3K |
| 8 | Kintz Samuel | Pres AND CEO, Dir | — | $613.6K |
| 9 | Heyman Richard A. | Dir | — | $413.4K |
Transactions 36
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-12 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
| MI | 2026-01-13 | 2026-01-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $27.98 | -48.3K | 215.3K | -18% | -$1.35M |
| MI | 2025-12-10 | 2025-12-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $21.02 | -6,663 | 263.3K | -2% | -$140.1K |
| MI | 2025-11-12 | 2025-11-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $17.40 | -6,667 | 270.0K | -2% | -$116.0K |
| I | 2025-10-09 | 2025-10-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $20.10 | -6,667 | 276.6K | -2% | -$134.0K |
| I | 2025-09-10 | 2025-09-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $20.24 | -6,667 | 283.3K | -2% | -$134.9K |
| MI | 2025-08-11 | 2025-08-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.24 | -6,667 | 290.4K | -2% | -$121.6K |
| MI | 2025-07-09 | 2025-07-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $19.79 | -6,667 | 296.9K | -2% | -$132.0K |
| MI | 2025-06-11 | 2025-06-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $20.34 | -6,667 | 303.4K | -2% | -$135.6K |
| MI | 2025-05-09 | 2025-05-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.39 | -6,667 | 310.5K | -2% | -$122.6K |
| MI | 2025-04-09 | 2025-04-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.04 | -6,667 | 316.8K | -2% | -$120.3K |
| I | 2025-03-11 | 2025-03-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $21.44 | -6,667 | 323.3K | -2% | -$142.9K |
| DI | 2025-02-10 | 2025-02-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $21.93 | -6,667 | 330.0K | -2% | -$146.2K |
| DM | 2025-01-10 | 2025-01-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | M - OptEx | $1.81 | +21.7K | 21.7K | New | +$39.3K |
| DM | 2025-01-10 | 2025-01-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $24.18 | -21.7K | 0 | -100% | -$524.6K |
| DMI | 2025-01-10 | 2025-01-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $24.18 | -6,667 | 336.6K | -2% | -$161.2K |
| I | 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $30.00 | -716 | 343.3K | -0.2% | -$21.5K |
| MI | 2024-07-16 | 2024-07-12+ | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $25.06 | -50.0K | 345.6K | -13% | -$1.25M |
| D | 2024-06-10 | 2024-06-06 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | M - OptEx | $2.48 | +1,133 | 1,133 | New | +$2,810 |
| D | 2024-06-10 | 2024-06-06 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $20.06 | -1,133 | 0 | -100% | -$22.7K |
| D | 2024-05-16 | 2024-05-14 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.00 | -1,107 | 0 | -100% | -$27.7K |
| D | 2024-05-16 | 2024-05-14 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | M - OptEx | $2.48 | +1,107 | 1,107 | New | +$2,745 |
| D | 2024-05-13 | 2024-05-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.06 | -260 | 0 | -100% | -$6,516 |
| D | 2024-05-13 | 2024-05-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | M - OptEx | $2.48 | +260 | 260 | New | +$644.80 |
| D | 2024-05-08 | 2024-05-06 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | M - OptEx | $2.48 | +4,875 | 4,875 | New | +$12.1K |
| D | 2024-05-08 | 2024-05-06 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $22.72 | -4,875 | 0 | -100% | -$110.8K |
| D | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.03 | -17.5K | 0 | -100% | -$438.0K |
| D | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | M - OptEx | $2.48 | +14.9K | 17.5K | +574% | +$37.0K |
| M | 2024-04-10 | 2024-04-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.60 | -4,875 | 2,597 | -65% | -$90.7K |
| 2024-03-08 | 2024-03-06 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $15.64 | -4,875 | 7,472 | -39% | -$76.2K | |
| 2024-02-08 | 2024-02-06 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $15.11 | -4,875 | 12.3K | -28% | -$73.7K | |
| 2024-01-24 | 2024-01-22 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $15.14 | -4,875 | 17.2K | -22% | -$73.8K | |
| M | 2024-01-02 | 2023-12-28+ | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $15.01 | -13.5K | 22.1K | -38% | -$203.3K |
| M | 2023-12-27 | 2023-12-22+ | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $15.03 | -1,085 | 35.6K | -3% | -$16.3K |
| D | 2023-02-27 | 2023-02-23 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | A - Grant | — | +36.7K | 36.7K | New | — |
| DI | 2023-02-27 | 2023-02-23 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | A - Grant | — | +394.0K | 394.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations